Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03743571 · ClinicalTrials.gov registry record · NA
Augmenting Exposure Therapy for Social Anxiety With Transcranial Direct Current Stimulation
A NA study, sponsored by University of Nevada, Reno.
- Terminated
- Registry status
- NA
- Development phase
- 33
- Enrollment target
NCT03743571: Clinical Trial NA study, sponsored by University of Nevada, Reno.
NCT03743571 is a NA study that was terminated before completion, run by University of Nevada, Reno. The registered enrollment target is 33 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03743571, a NA study, was terminated before completion, sponsored by University of Nevada, Reno.
- TERMINATED
- Registry status
- NA
- Development phase
- 33 participants
- Enrollment target
Study Summary
This study will examine whether transcranial direct current stimulation (tDCS) can be used to improve outcomes from exposure therapy for social anxiety disorder, and facilitate extinction of fear responding toward individuals outside one's own ethnic group (i.e., ethnic out-group members).
Primary Outcome
During Behavioral Approach Tests (BATs), participants will provide a speech to (a) an audience primarily matched to their ethnicity, and (b) an audience primarily un-matched to their ethnicity. The speech will be for up to 5 minutes in duration. During each BAT, we will assess fear response behaviorally (length of the speech, up to 5 min in duration) and subjectively (self reported levels of anticipated and peak fear). \*\*\*This outcome report is for the duration of the matched BAT. The total
Interventions
- DEVICE transcranial direct current stimulation
- BEHAVIORAL exposure therapy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 33 participants |
| Start Date | 2019-04-02 |
| Est. Completion | 2020-03-05 |
| Phase | NA |
Why NCT03743571 stopped before completion
NCT03743571 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 33 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower).
The record links to 0 conditions, and to 2 interventions - of which transcranial direct current stimulation is the first listed.
NCT03743571 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03743571 about?
NCT03743571 is a clinical study titled "Augmenting Exposure Therapy for Social Anxiety With Transcranial Direct Current Stimulation". This study will examine whether transcranial direct current stimulation (tDCS) can be used to improve outcomes from exposure therapy for social anxiety disorder, and facilitate extinction of fear responding toward individuals outside one's own ethnic group (i.e., ethnic out-group members).
What is the current status of trial NCT03743571?
This trial is currently terminated. It is a NA study. The enrollment target is 33 participants. The study started on 2019-04-02. Estimated completion is 2020-03-05.
What interventions are being tested in trial NCT03743571?
The interventions under investigation include: transcranial direct current stimulation (DEVICE), exposure therapy (BEHAVIORAL).
Who is sponsoring clinical trial NCT03743571?
This trial is sponsored by University of Nevada, Reno, which has 23 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03743571's enrollment target sits among peer trials
33 1574th of 2000 higher than 423 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02861898 · 33 participants · Phase 1
Super-selective Intra-arterial Repeated Infusion of Cetuximab for the Treatment of Newly Diagnosed Glioblastoma
- NCT04871607 · 33 participants · Phase 2
Yttrium-90 Labeled Anti-CD25 Monoclonal Antibody Combined With BEAM Chemotherapy Conditioning for the Treatment of Primary Refractory or Relapsed Hodgkin Lymphoma
- NCT05071937 · 33 participants · Phase 2
ZEN003694 Combined With Talazoparib in Patients With Recurrent Ovarian Cancer
- NCT05168618 · 33 participants · Phase 2
Cabozantinib and Atezolizumab for the Treatment of Metastatic Castration-Resistant Prostate Cancer, The AtezoCab Trial
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI